James E Kendrick
Overview
Explore the profile of James E Kendrick including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
32
Citations
311
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Awada A, Recio F, Kuhn T, Ahmad S, Zhu J, McKenzie N, et al.
Gynecol Oncol Rep
. 2025 Feb;
57:101684.
PMID: 39944179
Objective: To compare clinical outcomes of patients with early-stage, high-intermediate risk (HIR) endometrial cancer (EC) and isolated tumor cells (ITC) lymph node metastases treated with chemotherapy/radiotherapy (CRT) vs. external beam...
2.
Kuhn T, Ahmad S, Recio F, Awada A, McKenzie N, Kendrick J, et al.
Int J Gynecol Cancer
. 2024 Jun;
34(7):977-984.
PMID: 38830645
Objectives: External beam radiation with sensitizing platinum is the recommended therapy for locally advanced vulvar cancers not amenable to curative surgery and is associated with considerable acute and chronic side...
3.
Gwacham N, Kilowski K, Recio F, Awada A, Kuhn T, Zhu J, et al.
Gynecol Oncol
. 2023 Jun;
175:93-96.
PMID: 37329874
Background: Malignant peritoneal cytology in endometrial cancer (EC) is not considered an independent adverse prognostic factor for uterine-confined disease and is not a determinant factor in the International Federation of...
4.
Holloway R, Mendivil A, Kendrick J, Abaid L, Brown J, LeBlanc J, et al.
JAMA Oncol
. 2023 May;
9(7):903-908.
PMID: 37227734
Importance: Patients with platinum-resistant or platinum-refractory ovarian cancer (PRROC) have limited therapeutic options, representing a considerable unmet medical need. Objective: To assess antitumor activity and safety of intraperitoneal (IP) olvimulogene...
5.
Manyam M, Stephens A, Kennard J, LeBlanc J, Ahmad S, Kendrick J, et al.
Gynecol Oncol
. 2022 Feb;
165(2):401.
PMID: 35219528
No abstract available.
6.
Fitzsimmons C, Stephens A, Kennard J, Manyam M, Pepe J, Ahmad S, et al.
Ann Surg Oncol
. 2021 Nov;
29(3):2006-2013.
PMID: 34757549
Purpose: Minimally invasive radical hysterectomy has been associated with increased recurrence of disease and worse survival compared with open radical hysterectomy for early-stage cervical cancer. We evaluated patterns of recurrence...
7.
Manyam M, Stephens A, Kennard J, LeBlanc J, Ahmad S, Kendrick J, et al.
Gynecol Oncol
. 2021 Oct;
163(3):481-489.
PMID: 34686353
Objective: Our objective was to assess safety and adverse events associated with intraperitoneal Olvi-Vec virotherapy in patients with platinum-resistant or refractory ovarian cancer (PRROC). Secondary objectives included objective response rate...
8.
Stephens A, Kennard J, Fitzsimmons C, Manyam M, Kendrick J, Singh C, et al.
Int J Gynecol Cancer
. 2019 Dec;
30(3):305-310.
PMID: 31857439
Purpose: To establish the bilateral pelvic concordance rate of the sentinel lymph node (SLN) and determine the likelihood of lymph node metastasis in cases of mapping failure. Methods: A database...
9.
Rakowski J, Holloway R, Ahmad S, Jeppson C, James J, Ghurani G, et al.
Gynecol Oncol
. 2019 Oct;
155(3):468-472.
PMID: 31601494
Objective: To determine which non-narcotic analgesic, acetaminophen (Ofirmev®) or ketorolac (Toradol®), provides better post-operative pain control when combined with an opioid patient-controlled analgesia (PCA) pump. Secondary objectives include comparisons of...
10.
Kennard J, Stephens A, Ahmad S, Zhu X, Singh C, McKenzie N, et al.
Gynecol Oncol
. 2019 Apr;
154(1):53-59.
PMID: 31027899
Objectives: To examine sentinel lymph node pathology and describe relationships to uterine pathology, non-sentinel pelvic lymph nodes, and para-aortic lymph nodes. Methods: Patients with apparent uterine-confined endometrial cancer underwent robotic...